Insider Urges: Get Out Of Cash Before April 27th
Chris Rowe says there’s a huge stock market event looming - and he’s revealing his #1 pick for free.
Click here to find out more.
pixel

ARWR Insider Trading (Arrowhead Pharmaceuticals)

Insider Ownership Percentage: 4.00%
Insider Buying (Last 12 Months): $15,665.00
Insider Selling (Last 12 Months): $38,978,366.71

Arrowhead Pharmaceuticals Insider Trading History Chart

Arrowhead Pharmaceuticals Share Price & Price History

$62.15
▼ -1.56 (-2.45%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Finance PhD: Move Your Money Before April 30th
The clock just starting ticking on the biggest financial event in 20 years. The next few weeks could decide your wealth in 2021.
See what you should do now

Arrowhead Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2021Patrick O'brienGeneral CounselSell90,000$88.46$7,961,400.00383,375  
1/15/2021Douglas B. GivenDirectorSell3,000$83.28$249,840.00  
1/14/2021James C HamiltonSVPSell10,000$81.29$812,900.00130,064  
1/12/2021Kenneth Allen MyszkowskiCFOSell13,038$81.02$1,056,338.76445,446  
1/7/2021James HassardInsiderSell15,625$75.00$1,171,875.00109,375  
1/6/2021Kenneth Allen MyszkowskiCFOSell30,625$72.44$2,218,475.00486,568  
1/6/2021Patrick O'brienGeneral CounselSell25,000$72.41$1,810,250.00317,233  
1/5/2021James C HamiltonSVPSell19,375$72.53$1,405,268.75171,200  
1/4/2021Douglas B GivenDirectorSell4,000$76.08$304,320.00
12/17/2020Douglas B. GivenDirectorSell9,575$79.32$759,489.00  
12/10/2020William D WaddillDirectorSell3,000$71.26$213,780.0026,800  
12/9/2020Christopher Richard AnzaloneCEOSell38,676$69.06$2,670,964.562,521,561  
11/19/2020Martin Javier SanInsiderSell19,500$69.39$1,353,105.00130,500  
10/23/2020Christopher Richard AnzaloneCEOSell100,000$58.21$5,821,000.00  
10/20/2020Kenneth Allen MyszkowskiCFOSell29,166$54.04$1,576,130.64456,834  
10/9/2020Mauro FerrariDirectorSell10,000$48.00$480,000.0030,971  
8/13/2020Christopher Richard AnzaloneCEOSell50,000$41.35$2,067,500.002,655,237  
6/25/2020Christopher Richard AnzaloneCEOSell100,000$38.81$3,881,000.002,605,260  
6/15/2020Backer Marianne DeDirectorBuy500$31.33$15,665.0013,000  
5/12/2020Michael S PerryDirectorSell36,000$35.83$1,289,880.0014,100  
4/27/2020Bruce D GivenCOOSell300$40.00$12,000.00851,934  
4/20/2020Bruce D GivenCOOSell23,515$40.00$940,600.00862,793  
4/14/2020Douglas B GivenDirectorSell25,000$36.89$922,250.00155,925  
3/16/2020Backer Marianne DeDirectorBuy500$23.94$11,970.0013,000  
3/11/2020Backer Marianne DeDirectorBuy500$28.60$14,300.0013,000  
2/27/2020Backer Marianne DeDirectorBuy500$35.07$17,535.0013,000  
1/21/2020Kenneth Allen MyszkowskiCFOSell40,313$49.44$1,993,074.72424,536  
1/13/2020Backer Marianne DeDirectorBuy500$54.95$27,475.0013,000  
1/6/2020Bruce D GivenCOOSell35,613$60.13$2,141,409.69882,759  
1/6/2020Kenneth Allen MyszkowskiCFOSell20,000$60.11$1,202,200.00403,592  
1/6/2020Patrick O'brienGeneral CounselSell14,625$60.12$879,255.00267,406  
12/12/2019Christopher Richard AnzaloneCEOSell100,000$67.50$6,750,000.002,048,684  
12/2/2019Christopher Richard AnzaloneCEOSell37,967$69.15$2,625,418.052,116,160  
11/1/2019Kenneth Allen MyszkowskiCFOSell37,884$40.85$1,547,561.40351,420  
10/10/2019Christopher Richard AnzaloneCEOSell56,325$31.83$1,792,824.752,178,228  
9/24/2019Christopher Richard AnzaloneCEOSell66,645$28.20$1,879,389.002,146,153  
9/20/2019Christopher Richard AnzaloneCEOSell4,250$29.00$123,250.002,146,153  
9/11/2019Michael S PerryDirectorSell85,000$30.00$2,550,000.00121,000  
9/9/2019Michael S PerryDirectorSell100,000$28.90$2,890,000.00121,000  
6/26/2019Mauro FerrariDirectorSell17,756$27.61$490,243.161,900  
5/28/2019Patrick O'brienGeneral CounselSell30,000$24.88$746,400.00203,000  
5/21/2019Kenneth Allen MyszkowskiCFOSell27,071$22.00$595,562.00278,536  
4/3/2019Christopher Richard AnzaloneCEOSell50,000$19.30$965,000.00  
3/1/2019Bruce D GivenCOOSell42,500$19.99$849,575.00687,106  
2/26/2019Douglas B GivenDirectorSell65,000$19.25$1,251,250.00175,130  
2/25/2019Bruce D GivenCOOSell42,500$18.98$806,650.00687,106  
2/22/2019Douglas B GivenDirectorSell3,000$18.05$54,150.00175,130  
2/19/2019Bruce D GivenCOOSell68,750$17.86$1,227,875.00644,606  
2/19/2019Kenneth Allen MyszkowskiCFOSell8,000$18.00$144,000.00313,607  
2/15/2019Bruce D GivenCOOSell26,250$17.67$463,837.50644,606  
2/12/2019Bruce D GivenCOOSell242,834$16.04$3,895,057.36859,523  
2/8/2019Bruce D GivenCOOSell46,167$15.34$708,201.78859,523  
2/5/2019Bruce D GivenCOOSell22,500$14.48$325,800.00847,856  
2/1/2019Bruce D GivenCOOSell28,500$13.85$394,725.00870,356  
1/23/2019Bruce D GivenCOOSell169,500$13.54$2,295,030.00916,356  
1/22/2019Douglas B GivenDirectorSell3,000$13.58$40,740.00178,130  
1/18/2019Patrick O'brienGeneral CounselSell72,000$14.43$1,038,960.00233,000  
1/17/2019Kenneth Allen MyszkowskiCFOSell81,875$14.55$1,191,281.25305,607  
1/14/2019Bruce D GivenCOOSell42,666$14.40$614,390.401,110,022  
1/14/2019Zhen LiVPSell40,500$14.34$580,770.00201,700  
1/11/2019William D WaddillDirectorSell8,500$14.77$125,545.0046,500  
1/2/2019Bruce D GivenCOOSell20,000$11.98$239,600.001,118,356  
1/2/2019Kenneth Allen MyszkowskiCFOSell8,333$11.98$99,829.34395,815  
12/27/2018Douglas B. GivenDirectorSell3,000$12.00$36,000.00  
12/19/2018Christopher Richard AnzaloneCEOSell90,000$13.92$1,252,800.00  
12/12/2018Christopher Richard AnzaloneCEOSell90,000$14.07$1,266,300.00  
11/23/2018Douglas B. GivenDirectorSell3,000$12.74$38,220.00  
11/9/2018Christopher Richard AnzaloneCEOSell81,500$14.39$1,172,785.001,727,755  
10/19/2018Peter Brian LeoneVPSell131,137$13.49$1,769,038.13160,000  
9/6/2018Kenneth Allen MyszkowskiCFOSell45,000$19.34$870,300.00335,815  
9/4/2018Christopher Richard AnzaloneCEOSell164,834$14.45$2,381,851.301,868,789  
8/31/2018Christopher Richard AnzaloneCEOSell100,000$14.45$1,445,000.001,868,789  
6/19/2018Kenneth Allen MyszkowskiCFOSell20,000$14.01$280,200.00330,815  
5/31/2018Kenneth Allen MyszkowskiCFOSell14,000$11.00$154,000.00312,215  
4/24/2018Douglas B. GivenDirectorSell25,000$6.63$165,750.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

65.52% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arrowhead Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/9/2021State of Alaska Department of Revenue16,262$1.08M0.0%-2.6%0.016%
4/5/2021Pacer Advisors Inc.12,130$0.80M0.0%-7.8%0.012%
4/5/2021Fulton Bank N.A.3,827$0.25M0.0%+4.4%0.004%
3/24/2021IronBridge Private Wealth LLC455$35K0.0%N/A0.000%
3/12/2021DekaBank Deutsche Girozentrale36,850$2.87M0.0%-17.6%0.036%
3/9/2021Amundi Pioneer Asset Management Inc.600$46K0.0%-34.4%0.001%
3/8/2021Dimensional Fund Advisors LP232,300$17.83M0.0%-29.2%0.224%
3/2/2021Norges Bank858,781$65.89M0.0%N/A0.827%
3/2/2021Capital Asset Advisory Services LLC3,000$0.23M0.0%N/A0.003%
3/1/2021UBS Asset Management Americas Inc.117,596$9.02M0.0%+10.8%0.113%
2/25/2021Dimensional Fund Advisors LP232,300$17.83M0.0%-29.2%0.224%
2/25/2021Hsbc Holdings PLC9,078$0.70M0.0%N/A0.009%
2/24/2021Virtu Financial LLC25,626$1.97M0.2%N/A0.025%
2/23/2021WCM Investment Management LLC151,895$11.66M0.0%+0.3%0.146%
2/23/2021Principal Financial Group Inc.344,738$26.45M0.0%+3.9%0.332%
2/19/2021JPMorgan Chase & Co.2,409,631$184.89M0.0%+64.3%2.322%
2/18/2021Truist Financial Corp9,700$0.75M0.0%N/A0.009%
2/17/2021Voloridge Investment Management LLC92,355$7.09M0.1%N/A0.089%
2/17/2021Castleark Management LLC65,490$5.03M0.2%-17.9%0.063%
2/17/2021Cim Investment Mangement Inc.6,306$0.48M0.2%+2.0%0.006%
2/17/2021Canada Pension Plan Investment Board901$69K0.0%N/A0.001%
2/17/2021Cetera Investment Advisers115,090$8.83M0.2%+521.2%0.111%
2/16/2021London & Capital Asset Management Ltd13,000$1M0.1%N/A0.013%
2/16/2021Tri Locum Partners LP56,003$4.30M1.6%N/A0.054%
2/16/2021Morgan Stanley536,479$41.16M0.0%+4.4%0.517%
2/16/2021Nuveen Asset Management LLC709,838$54.47M0.0%-0.2%0.684%
2/16/2021Captrust Financial Advisors4,200$0.32M0.0%+13.5%0.004%
2/16/2021WCM Investment Management LLC151,895$11.66M0.0%+0.3%0.146%
2/16/2021Guggenheim Capital LLC51,313$3.94M0.0%-42.6%0.049%
2/16/2021Price T Rowe Associates Inc. MD55,467$4.26M0.0%-22.2%0.053%
2/16/2021Amundi Pioneer Asset Management Inc.600$46K0.0%-34.4%0.001%
2/16/2021Hood River Capital Management LLC393,263$30.18M1.0%+2.1%0.379%
2/16/2021Virginia Retirement Systems ET AL10,600$0.81M0.0%-22.1%0.010%
2/16/2021Schroder Investment Management Group68,118$5.23M0.0%+0.9%0.066%
2/16/2021Janus Henderson Group PLC1,145,443$87.89M0.0%-1.1%1.104%
2/16/2021ExodusPoint Capital Management LP10,807$0.83M0.0%N/A0.010%
2/16/2021Acuta Capital Partners LLC139,000$10.67M2.9%+36.9%0.134%
2/16/2021Parametrica Management Ltd3,335$0.26M0.2%N/A0.003%
2/16/2021Charles Schwab Investment Management Inc.927,495$71.17M0.0%+1.4%0.894%
2/13/2021American International Group Inc.245,335$18.83M0.1%-0.3%0.236%
2/12/2021Capital Impact Advisors LLC88,183$6.77M1.7%-50.5%0.085%
2/12/2021Uniplan Investment Counsel Inc.75,752$5.81M0.4%-1.8%0.073%
2/12/2021Bamco Inc. NY664,637$51M0.1%+78.9%0.640%
2/12/2021Federated Hermes Inc.53,510$4.11M0.0%+188.6%0.052%
2/12/2021LPL Financial LLC8,893$0.68M0.0%-22.3%0.009%
2/12/2021Raymond James Financial Services Advisors Inc.20,587$1.58M0.0%-31.4%0.020%
2/12/2021Amalgamated Bank16,585$1.27M0.0%+1.0%0.016%
2/12/2021Public Employees Retirement System of Ohio1,870$0.14M0.0%N/A0.002%
2/12/2021The Manufacturers Life Insurance Company181,369$13.92M0.0%-4.4%0.175%
2/12/2021Vontobel Holding Ltd.7,800$0.60M0.0%N/A0.008%
2/12/2021Virtus ETF Advisers LLC3,938$0.30M0.1%-58.2%0.004%
2/11/2021Nikko Asset Management Americas Inc.158,731$12.18M0.1%N/A0.153%
2/11/2021B. Riley Wealth Management Inc.4,500$0.35M0.0%N/A0.004%
2/11/2021Northern Trust Corp1,558,425$119.58M0.0%-2.3%1.501%
2/11/2021First Mercantile Trust Co.1,646$0.13M0.0%-19.6%0.002%
2/11/2021Barclays PLC164,396$12.62M0.0%-17.4%0.158%
2/11/2021Handelsbanken Fonder AB18,500$1.42M0.0%+17.1%0.018%
2/11/2021Teacher Retirement System of Texas8,914$0.68M0.0%+59.4%0.009%
2/11/2021First Horizon Advisors Inc.1,053$80K0.0%+18.0%0.001%
2/11/2021Oppenheimer Asset Management Inc.17,048$1.31M0.0%-1.8%0.016%
2/10/2021Rhumbline Advisers297,640$22.84M0.0%-0.7%0.287%
2/10/2021King Luther Capital Management Corp69,615$5.34M0.0%N/A0.067%
2/10/2021Keystone Financial Group3,800$0.29M0.1%N/A0.004%
2/10/2021QS Investors LLC8,923$0.69M0.0%-28.5%0.009%
2/10/2021Level Four Advisory Services LLC2,614$0.20M0.0%N/A0.003%
2/10/2021KBC Group NV2,655$0.20M0.0%-37.7%0.003%
2/10/2021HighTower Advisors LLC12,008$0.92M0.0%+54.8%0.012%
2/10/2021Lisanti Capital Growth LLC103,955$7.98M1.1%N/A0.100%
2/10/2021LS Investment Advisors LLC6,784$0.52M0.0%-15.9%0.007%
2/9/2021Wells Fargo & Company MN266,840$20.48M0.0%+13.1%0.257%
2/9/2021Hancock Whitney Corp19,045$1.46M0.0%-13.7%0.018%
2/9/2021Fiera Capital Corp1,275,339$97.86M0.3%+2.2%1.229%
2/9/2021ClariVest Asset Management LLC51,090$3.92M0.1%-35.9%0.049%
2/9/2021Seven Eight Capital LP15,030$1.15M0.3%-1.2%0.014%
2/9/2021Keybank National Association OH3,229$0.25M0.0%N/A0.003%
2/9/2021Bank of New York Mellon Corp1,037,071$79.57M0.0%-2.2%0.999%
2/9/2021Quantitative Systematic Strategies LLC5,186$0.40M0.1%N/A0.005%
2/9/2021Oregon Public Employees Retirement Fund33,933$2.60M0.0%-2.0%0.033%
2/9/2021Blair William & Co. IL22,140$1.70M0.0%-4.9%0.021%
2/9/2021Mitsubishi UFJ Kokusai Asset Management Co. Ltd.3,532$0.27M0.0%-33.1%0.003%
2/9/2021ProShare Advisors LLC46,143$3.54M0.0%+29.3%0.044%
2/9/2021Profund Advisors LLC9,893$0.76M0.0%+6.8%0.010%
2/8/2021Alliancebernstein L.P.305,992$23.48M0.0%-3.9%0.295%
2/8/2021Principal Financial Group Inc.344,738$26.45M0.0%+3.9%0.332%
2/8/2021State Board of Administration of Florida Retirement System42,802$3.28M0.0%-1.0%0.041%
2/8/2021New York State Common Retirement Fund376,392$28.88M0.0%+2.6%0.363%
2/8/2021Sei Investments Co.28,619$2.20M0.0%+89.5%0.028%
2/8/2021Tygh Capital Management Inc.86,512$6.64M1.0%+55.2%0.083%
2/8/2021Russell Investments Group Ltd.107,058$8.22M0.0%+70.4%0.103%
2/5/2021IndexIQ Advisors LLC7,280$0.56M0.0%+11.5%0.007%
2/5/2021BlackRock Inc.12,563,132$963.97M0.0%+0.0%12.104%
2/5/2021Costello Asset Management INC800$61K0.0%+60.0%0.001%
2/5/2021Aperio Group LLC24,193$1.86M0.0%+21.0%0.023%
2/5/2021Swiss National Bank219,700$16.86M0.0%+0.3%0.212%
2/5/2021Redwood Investments LLC6,279$0.48M0.0%N/A0.006%
2/5/2021Sumitomo Mitsui Trust Holdings Inc.158,731$12.18M0.0%N/A0.153%
2/5/2021SG Americas Securities LLC38,829$2.98M0.0%-19.5%0.037%
2/4/2021Los Angeles Capital Management LLC40,456$3.10M0.0%-10.4%0.039%
2/4/2021Foundry Partners LLC13,939$1.07M0.0%N/A0.013%
2/4/2021Texas Permanent School Fund85,303$6.55M0.1%-10.7%0.082%
Data available starting January 2016

See Full Table
Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $62.15
$61.29
$63.25

50 Day Range

MA: $71.98
$61.35
$89.51

52 Week Range

Now: $62.15
$30.83
$92.60

Volume

783,255 shs

Average Volume

825,239 shs

Market Capitalization

$6.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' top insider shareholders include:
  1. Christopher Richard Anzalone (CEO)
  2. Bruce D Given (COO)
  3. Kenneth Allen Myszkowski (CFO)
  4. Patrick O'brien (General Counsel)
  5. James C Hamilton (SVP)
  6. Douglas B Given (Director)
  7. Martin Javier San (Insider)
  8. Michael S Perry (Director)
  9. James Hassard (Insider)
  10. Mauro Ferrari (Director)
  11. William D Waddill (Director)
  12. Backer Marianne De (Director)
  13. Douglas B Given (Director)

Who are the major institutional investors of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' top institutional shareholders include:
  1. State of Alaska Department of Revenue — 0.02%
  2. Pacer Advisors Inc. — 0.01%
  3. Fulton Bank N.A. — 0.00%

Which institutional investors are selling Arrowhead Pharmaceuticals stock?

During the last quarter, ARWR stock was sold by these institutional investors:
  1. Pacer Advisors Inc.
  2. State of Alaska Department of Revenue
In the last year, company insiders that have sold Arrowhead Pharmaceuticals company stock include:
  1. Christopher Richard Anzalone (CEO)
  2. Bruce D Given (COO)
  3. Kenneth Allen Myszkowski (CFO)
  4. Patrick O'brien (General Counsel)
  5. James C Hamilton (SVP)
  6. Douglas B Given (Director)
  7. Martin Javier San (Insider)
  8. Michael S Perry (Director)
  9. James Hassard (Insider)
  10. Mauro Ferrari (Director)
  11. William D Waddill (Director)
  12. Backer Marianne De (Director)

Which institutional investors are buying Arrowhead Pharmaceuticals stock?

Within the last quarter, ARWR stock was acquired by institutional investors including:
  1. Fulton Bank N.A.
April 30th is approaching, are you prepared?
A new president’s policies always influence key stocks.
Here’s where top billionaires are investing.
pixel